SAHIBU SULTAN M. HABEEBU, M.D., PH.D.

VISA STATUS/CITIZENSHIP: Citizen of the United States of America MEDICAL EDUCATION 1974–1980 University of Lagos Lagos, Nigeria M.B, B.S. (M.D. equivalent) GRADUATE EDUCATION 1986–1990 University of Cambridge Cambridge, United Kingdom Ph.D., Medical Genetics UNDERGRADUATE EDUCATION 1977–1978 University of Lagos Lagos, Nigeria B.S., Anatomic Pathology (This program was intercalated with my Medical Education) RESIDENCY AND FELLOWSHIP TRAINING PROGRAMS 2007–2008 Children's Mercy Hospitals and Clinics Kansas City, MO, USA David Zwick, M.D., Program Director Fellowship Training: Pediatric Pathology 2005–2007 Baylor College of Medicine, Texas Children’s Hospital, and MD Anderson Cancer

Center, Houston, TX, USA James Versalovic, M.D., Ph.D., then Program Director, now Dept. Chair Fellowship Training: Molecular Genetic Pathology 2001–2005 Kansas University Medical Center, Kansas City, KS, USA Diane Persons, M.D., Program Director Residency: Pathology (AP/CP) 1990–1994 The Royal London Hospital, University of London, U.K. Sir Colin Berry, M.D., Ph.D., FRCPath, Professor of Anatomic Pathology Residency: Anatomic Pathology 1982–1986 Lagos University Teaching Hospital, Lagos, Nigeria E. O. Odunjo, M.D., FWACP, Professor of Anatomic Pathology Residency: Anatomic Pathology

1 of 12

EMPLOYMENT 2011 to date Pathologist, Departments of Pathology, St. Louis University and Cardinal

Glennon Children’s Medical Center, St. Louis, MO. 2007–2008 Pediatric Pathology Fellow, Department of Pathology and Laboratory Medicine,

Children's Mercy Hospitals and Clinics, Kansas City, MO. 2005–2007 Molecular Genetic Pathology (MGP) Fellow, Department of Pathology, Baylor

College of Medicine, Houston, TX (Program Director: James Versalovic, MD, PhD), with rotations at Texas Children’s Hospital, MD Anderson Cancer Center (MGP Program Director: Daniel Jones, MD), and Baylor College of Medicine’s Medical Genetics Laboratories (Director: Christine M. Eng, MD), all in Houston, TX.

2001–2005 Resident, Department of Pathology, University of Kansas Medical Center,

Kansas City, KS. 1994–2001 Postdoctoral Fellow, Department of Pharmacology, Toxicology and Therapeutics,

University of Kansas Medical Center, Kansas City, KS. 1990–1994 Lecturer, Department of Morbid Anatomy (Anatomic Pathology in U.S.), The

London Hospital Medical College, University of London, and Senior Resident in Anatomic Pathology, The Royal London Hospital, London, U.K. (The London Hospital Medical College and The Royal London Hospital are the academic and clinical service arms, respectively, of the same medical institution).

1981–1982 One year National Service (National Youth Service Corps, Nigeria), with the

National Sports Commission of Nigeria. Worked as the National Secretary of the National Association for Sports Medicine.

1980–1981 Internship consisting of 3 months each in Internal Medicine, Surgery, Pediatrics,

and Obstetrics and Gynecology, Lagos University Teaching Hospital, Lagos, Nigeria.

RESEARCH EXPERIENCE Molecular Genetic Pathology Fellow, Department of Pathology, Baylor College of Medicine, Houston, TX, July 2005 to June 2007: • Assay development and validation using molecular techniques including endpoint PCR, RT-

PCR, quantitative RT-PCR, long range PCR, pyrosequencing, dideoxy-termination (or modified Sanger) sequencing and capillary electrophoresis:

- TEL/AML1 fusion transcript in childhood acute lymphoblastic leukemia, using real-time

quantitative PCR and dideoxy-termination sequencing. The TEL/AML1 rearrangement is the most common rearrangement in childhood ALL. I developed this assay in Dr. D. L. Lopez-Terrada’s Molecular Oncology Laboratory at Texas Children’s Hospital.

2 of 12

- JAK2 V617F mutation detection and allele quantitation in chronic myeloproliferative disorders, using endpoint PCR and pyrosequencing. The JAK2 V617F mutation is present in varying percentages of cases of polycythemia vera, essential thrombocytemia, idiopathic myelofibrosis, juvenile myelomonocytic leukemia, and bcr/abl-negative chronic myeloid leukemia. I developed this assay in Dr. D. L. Lopez-Terrada’s Molecular Oncology Laboratory at Texas Children’s Hospital.

- Deletion of exons 4 through 10 (11 kb genomic deletion) in the NEMO (NF-kB Essential

MOdulator) gene, in incontinentia pigmenti, using long range PCR and gel electrophoresis. The assay necessarily distinguishes the NEMO deletion from an identical deletion in the NEMO gene (NEMO pseudogene) located 32 kb away from the NEMO gene on Xq28. I developed this assay in Baylor College of Medicine’s Medical Genetics Laboratories.

- Mutations in the Runx2 gene, responsible for cleidocranial dysostosis, a form of skeletal

dysplasia. Assay involves endpoint PCR, dideoxy-termination sequencing and mutation analysis. I developed this assay in Baylor College of Medicine’s Medical Genetics Laboratories.

• Other projects: - Role of uridine diphosphate-glucuronosyltransferase isoform UGT1A1 promoter

polymorphisms (TA repeats) in the prognosis and adverse responses of Philadelphia chromosome-positive acute lymphoblastic leukemia patients to chemotherapy. This study involved endpoint PCR, pyrosequencing and capillary electrophoresis, and is part of a larger, MD Anderson Cancer Center’s pharmacogenomic study that includes polymorphisms in the genes of glutathione-S-transferase isozyme GSTT1 and thymidylate synthase.

- Molecular distinction between hepatoblastomas and hepatocellular carcinomas using

quantitative FISH (fluorescence in situ hybridization) on tissue sections. I am investigating the possibility of using variations in the copy number of specific chromosomes (aneuploidy) or chromosome regions to distinguish one tumor from the other. Our data indicates that quantitative FISH analysis, using our targeted chromosomal regions, does not sufficiently distinguish hepatoblastomas from hepatocellular carcinomas.

- Mutations in the -catenin gene in desmoid tumors. This mutation has been reported in a

large number of desmoid tumors and I am investigating the possibility of using this mutation as a tumor marker in the development of a molecular assay for the diagnosis of desmoid tumors. This study has demonstrated that the incidence of single point mutations in the beta-catenin gene is sufficiently high for the mutations to be used in the molecular diagnosis of sporadic desmoid tumors.

Postdoctoral Fellow, Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, 1994–2001; Mentor: Curtis D. Klaassen, PhD. Experience in generating research ideas, designing and performing experiments, presenting my work in scientific conferences, and publishing my work in reputable journals. • Acute toxicological effects of cadmium on the liver and kidney, using animal models.

Involved many laboratory techniques, including histology (histopathology) immunohisto-

3 of 12

chemistry, confocal microscopy, toxicological/biochemical techniques, atomic adsorption spectroscopy, image analysis, and handling of radioisotopes and laboratory animals.

• Chronic toxicological effects of cadmium on the liver, kidney, brain and bone, using the

same techniques listed above. • Role of metallothionein, an anti-oxidant and heavy metal chelator, in protecting against

acute and chronic cadmium toxicity, using same techniques listed above. • Arsenic and cisplatin toxicity to the liver and kidney, respectively, using animal models,

atomic adsorption spectroscopy, histopathology and immunohistochemistry. • Liver transmembrane transporters and their role in the metabolism of bile acids and

xenobiotics, using immunohistochemistry and toxicological/biochemical assay techniques. Graduate student in Medical Genetics, Department of Pathology, University of Cambridge, Cambridge, United Kingdom, 1986–1990; Mentor: Malcolm Ferguson-Smith, MD. The first year of this program was spent at the University of Glasgow, Glasgow, United Kingdom. • I established a small laboratory devoted to the then still emerging research technique of

non-isotopic (non-radioactive) in situ hybridization. • I developed a biotin-based and a fluorescence-based non-isotopic in situ hybridization

technique for the rapid prenatal diagnosis of aneuploidy in interphase nuclei. • I developed a non-isotopic in situ hybridization technique for gene mapping, using

metaphase spreads. • I mapped 3 genes on the X and Y chromosomes and chromosome 9, as part of the search

for the gene(s) responsible for sex determination in humans. TEACHING AND OTHER ACADEMIC ASSIGNMENTS 2007 I taught a course in Molecular Diagnostics Technology to the medical laboratory

technologists in the Department of Pathology, Texas Children’s Hospital, March – April, 2007, Houston, TX.

2007 I taught “Molecular Pathology Techniques” to Pathology residents, January 2007,

at Baylor College of Medicine, Houston, TX. 2006 I taught “Introduction to Bioinformatics” to Pathology residents, January 2006, at

Baylor College of Medicine, Houston, TX. 2005 I taught some modules of the pathology of organ/systems to medical students,

Fall Semester, 2005, at the Department of Pathology, Baylor College of Medicine, Houston, TX.

4 of 12

1999 I taught “Principles of Toxicology (PTOX 918)” to graduate students, Fall Semester, 1999, at the Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, KS.

1992–1994 I taught “Pulmonary Pathology” to medical and dental students at the Department

of Morbid Anatomy (Anatomic Pathology in U.S.), The London Hospital Medical College, University of London, London, United Kingdom.

1988–1989 I served as mentor to a medical student during his one-year intercalated research

program at the Department of Pathology, University of Cambridge, Cambridge, United Kingdom.

PUBLICATIONS Peer Reviewed: 1. Ojikutu N.A., Odunjo E.O. and Habeebu S.S.: The Cranial Index in Indigenous Nigerians:

Anthropometric and Anatomical Study of 3,922 Cases. (1980). Nigerian Medical Journal, 10(1-2): 55–63, Jan.-Feb 1980.

2. Affara N.A., Chambers D., O’Brien J., Habeebu S.S.M., Kalaitsidaki M., Bishop C.E. and

Ferguson-Smith M.A.: Evidence for distinguishable transcripts of the putative testis determining gene (ZFY) and mapping of homologous cDNA sequences to chromosomes X, Y and 9. Nucleic Acids Research, 17(8): 2987–2999, Apr. 25, 1989.

3. Habeebu S.S.M., Spathas D.H. and Ferguson-Smith M.A.: Non-radioactive in situ

hybridization of DNA probes to chromosomes and nuclei: A comparison of techniques. Journal of Molecular Biology and Medicine, 7(5): 423–435, Oct. 1990.

4. Lloyd S.L., Sargent C.A., Chalmers J., Lim E., Habeebu S.S. and Affara N.A.: An X-linked

zinc finger gene mapping to Xq21.1–q21.3 closely related to ZFX and ZFY: possible origins from a common ancestral gene. Nucleic Acids Research, 19(18): 4835–41, Sept. 25, 1991.

5. Ramani P., Yeung C.K. and Habeebu S.S.M.: Testicular intratubular germ cell neoplasia in

children and adolescents with intersex. The American Journal of Surgical Pathology 17(11): 1124–1133, Nov. 1993.

6. Liu, J., Liu, Y-P., Habeebu, S.M., and Klaassen, C.D.: Metallothionein (MT)-null mice are

sensitive to cisplatin-induced hepatotoxicity. Toxicology and Applied Pharmacology, 149(1): 24–31, Mar. 1998.

7. Habeebu S.S.M., Liu, J. and Klaassen C.D.: Cadmium-Induced Apoptosis in Mouse Liver.

Toxicology and Applied Pharmacology, 149(2): 203–209, Apr. 1998. 8. Liu, J., Habeebu S.S.M., Liu, Y. and Klaassen C.D.: Acute CdMT injection is not a good

model to study chronic Cd nephropathy: Comparison of chronic CdCl2 and CdMT exposure with acute CdMT injections in rats. Toxicology and Applied Pharmacology, 153(1): 48–58, Nov. 1998.

5 of 12

9. Liu, J., Liu, Y., Habeebu S.S.M. and Klaassen C.D.: Susceptibility of MT-null mice to chronic CdCl2-induced nephrotoxicity indicates that renal injury is not mediated by the CdMT complex. Toxicological Sciences, 46(1): 197–203, Nov. 1998.

10. Liu, J., Liu, Y., Habeebu, S.S., and Klaassen, C.D.: Metallothionein-null mice are highly

susceptible to the hematotoxic and immunotoxic effects of chronic CdCl2 exposure. Toxicology and Applied Pharmacology, 159(2): 98–108, Sept. 1, 1999.

11. Liu, Y., Liu, J., Habeebu, S.S., and Klaassen, C.D.: Metallothionein protects against the

nephrotoxicity produced by chronic CdMT exposure. Toxicological Sciences. 50(2): 221–227, Aug. 1999.

12. Rojas, P., Rojas, J., Vigueras-Villaseñor, R.M., Habeebu, S.S.M. and Ebadi, M.: MPTP

decreases MT-1 mRNA in mouse striatum. Neurochemical Research. 25(4): 503–509, Apr. 2000.

13. Habeebu S.S.M., Liu, J., Liu, Y. and Klaassen C.D.: Metallothionein-null mice are more

sensitive than wild-type mice to liver injury induced by repeated exposure to cadmium. Toxicological Sciences. 55(1): 223–232, May 2000.

14. Habeebu S.S.M., Liu, J., Liu, Y. and Klaassen C.D.: Metallothionein-null mice are more

susceptible than wild type mice to chronic CdCl2-induced bone injury. Toxicological Sciences. 56(1): 211–219, July 2000.

15. Liu, J., Liu, Y., Habeebu, S.S.M., Waalkes, M.P., and Curtis D. Klaassen, C.D.: Chronic

combined exposure to cadmium and arsenic exacerbates nephrotoxicity, particularly in metallothionein-I/II null mice. Toxicology 147(3): 157–166, July 5, 2000.

16. Jeong, S-H., Habeebu, S.S.M. and Klaassen, C.D.: Cadmium decreases gap junctional

intercellular communication in mouse liver. Toxicological Sciences. 57(1): 156–166, Sept. 2000.

17. Liu, Y., Liu, J., Habeebu, S.S.M., Waalkes, M.P., and Curtis D. Klaassen, C.D.:

Metallothionein-I/II null mice are sensitive to chronic oral cadmium-induced nephrotoxicity. Toxicological Sciences. 57(1): 167–176, Sept. 2000.

18. Staudinger, J., Liu, Y., Madan, A., Habeebu, S. and Klaassen, C.D.: Coordinate regulation

of xenobiotic and bile acid homeostasis by pregnane X receptor. Drug Metabolism and Disposition. 29(11): 1467–72, Nov. 2001.

19. Habeebu, S.S.M., Liu, Y., Park, J.D. and Klaassen C.D.: Strain differences in the toxicity of cadmium to trigeminal ganglia in mice. Toxicology and Applied Pharmacology, 15; 177(3): 200–207, Dec. 2001.

20. Park, J.D., Habeebu, S.S., and Klaassen, C.D.: Testicular toxicity of di-(2-

ethylhexyl)phthalate in the young Sprague-Dawley rats. Toxicology, 171(2–3): 105–15, Feb. 28, 2002.

21. Johnson, D.R., Habeebu, S.S. and Klaassen, C.D.: Increase in bile flow and biliary

excretion of glutathione-derived sulfhydryls in rats by drug-metabolizing enzyme inducers is

6 of 12

mediated by multidrug resistance protein 2. Toxicological Sciences, 66(1): 16–26, Mar. 2002.

22. Vansell, N.R., Muppidi, J.R., Habeebu, S.M., and Klaassen, C.D.: Promotion of thyroid

tumors in rats by pregnenolone-16α-carbonitrile (PCN) and polychlorinated biphenyl (PCB). Tox. Sci. 81(1): 50–59, June 2004.

23. Lazar, A.J.F., Tuvin, D., Hajibashi, S. Habeeb, S., Bolshakov, S., Mayordomo-Aranda, E.,

Warneke, C.L., Lopez-Terrada, D., Pollock, R. E., and Lev, D. Specific Mutations in the β-Catenin Gene (CTNNB1) Correlate with Local Recurrence in Sporadic Desmoid Tumors. Am. J. Pathol. 173(5): 1518–1527, Nov. 2008.

24. Zhang W.W., Habeebu S., Sheehan A.M., Naeem R., Hernandez V.S., Dreyer Z.E., López-

Terrada D. Molecular monitoring of 8p11 myeloproliferative syndrome in an infant. J Pediatr Hematol Oncol 31(11): 879–83, Nov. 2009.

Book Chapters: 1. Klaassen, C.D. and Habeebu, S.S.M.: Role of metallothionein in cadmium-induced

hepatotoxicity. In: Trends in Biopharmaceutical and Toxicological Sciences, pages 1–17, Seoul National University Press, Seoul, South Korea, Apr. 1998.

2. Klaassen, C.D., Liu, J., Liu, Y., and Habeebu, S.S.: Metallothionein-null mice are

susceptible to CdCl2-induced nephropathy: Cd-induced renal injury is not necessarily mediated by CdMT. In: Metallothionein IV, Editor: Curtis D. Klaassen, pages 453–458. Birkhauser Verlag, Basel, Switzerland, 1999.

3. Ferreira-Gonzales, A., Versalovic, J., Habeebu, S. and Caliendo, A.M.: Molecular Methods

in Diagnosis and Monitoring of Infectious Diseases. In: Fundamentals of Molecular Diagnostics, Editors: David E. Bruns, Edward R. Ashwood and Carl A. Burtis, pages 171–196. Saunders Elsevier, St. Louis, MO, USA, 2007.

PRESENTATIONS 1. Spathas D.H., Habeebu S.S.M. and Ferguson-Smith M.A.: Non-radioactive in situ

hybridization: Comparisons in methodology. Clinical Genetics Society Conference. Oxford, U.K., April 1988. Abstract published in Journal of Medical Genetics 25(9): 644.

2. Ferguson-Smith M.E., Habeebu S.S.M., Spathas D. and Ferguson-Smith M.A.: Application

of in situ hybridization to diagnostic cytogenetics. Clinical Genetics Society Conference. Aberdeen, U.K., September 1988. Abstract published in Journal of Medical Genetics 26(3): 215.

3. Habeebu S.S.M., Gibson J., Affara N.A. and Ferguson-Smith M.A.: Localization of three

zinc finger genes using Southern analysis of somatic cell hybrid DNA and non-radioactive in situ hybridization. Clinical Genetics Society Conference. Southampton, U.K., March 1989.

7 of 12

4. Affara N.A., Chambers D., O’Brien J., Habeebu S.S.M., Kalaitsidaki M., Bishop C.E. and Ferguson-Smith M.A.: Distinguishable transcripts of the putative testis determining sequences share homology with loci on chromosomes X, Y and 9. International Genome Mapping and Sequencing Conference. Cold Spring Harbor, New York, April 1989.

5. Affara N.A., Chambers D., O’Brien J., Habeebu S.S.M., Kalaitsidaki M., Bishop C.E. and

Ferguson-Smith M.A.: Distinguishable transcripts of the putative testis determining sequences share homology with loci on chromosomes X, Y and 9. The Clinical Genetics Society Conference; Southampton, U.K., March 1989.

6. Affara N.A., Chambers D., O’Brien J., Habeebu S.S.M., Kalaitsidaki M., Bishop C.E. and

Ferguson-Smith M.A.: Distinguishable transcripts of the putative testis determining sequences share homology with loci on chromosomes X, Y and 9. The 10th Human Gene Mapping Conference; New Haven, Connecticut, June 1989. The abstract is published in Cytogenetics and Cell Genetics, 51:948, 1989.

7. Habeebu S.S.M., Gibson J.E., Affara N.A. and Ferguson-Smith M.A.: Localization of two

zinc finger protein genes to (a) two loci on chromosome 5 at 5p13–14 and 5q12–13 and (b) the long arm of the X at Xq13–q21.1. 10th International Human Gene Mapping Conference. New Haven, Connecticut, June 1989. Abstract published in Cytogenetics and Cell Genetics, 51:1009, 1989.

8. Willatt L.R., Ferguson-Smith M.E., Habeebu S.S.M., Carter N., Affara N.A. and Ferguson-

Smith M.A.: Three XX Males: A cytogenetic and molecular investigation. Association of Clinical Cytogeneticists. Birmingham, U.K., July 1989.

9. Habeebu S.S.M. and Ferguson-Smith M.A.: Diagnostic applications of in situ hybridization.

Pathological Society of Great Britain and Ireland. Cambridge, U.K., January 1991. 10. Habeebu S.S.M., Liu J. and Klaassen C.D.: Cadmium-Induced Apoptosis in Mouse Liver.

International Society of Toxicology. Anaheim, CA, March 1996. Abstract published in Fundamental and Applied Toxicology, 30(#1, Pt 2): 167, 1996.

11. Habeebu S.S.M., Liu J., Liu Y. and Klaassen C.D.: Acute CdMT injection is not a good

model to study chronic Cd nephropathy: Comparison of chronic CdCl2 and CdMT exposure with acute CdMT injections in rats. Kansas Health Foundation. Lawrence, KS, April 1997.

12. Habeebu, S.S.M., Liu J., Liu Y-P., and Klaassen C.D.: Metallothionein-null mice are

vulnerable to chronic CdCl2-induced hepatotoxicity. Fourth International Metallothionein Meeting. Kansas City, KS, September 1997.

13. Habeebu S.S.M., Liu J., Liu Y-P., and Klaassen C.D.: Metallothionein-null mice are more

susceptible than control mice to chronic Cd-induced osteotoxicity. International Society of Toxicology. Seattle, WA, March 1998.

14. Habeebu S.S.M., Liu J., Liu Y. and Klaassen C.D.: Cadmium pretreatment protects

metallothionein-null mice against testicular toxicity but not hepatotoxicity. International Society of Toxicology. New Orleans, LA, March 1999.

8 of 12

15. Habeebu S.S.M., Liu Y., Park J.D. and Klaassen C.D.: Strain differences in the toxicity of cadmium in trigeminal ganglia in mice. International Society of Toxicology. San Francisco, CA, March 2001.

16. Habeebu S.S.M., Patel K., Szabo S., Lazar A. and Lopez-Terrada D.:

Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion transcript: Newly developed RT-PCR assay identifies novel COL1A1 breakpoints. Presented at the Association for Molecular Pathology Annual Meeting, in Orlando, FL on November 16 – 19, 2006.

17. Chen S.S., Habeebu S.S.M., Galbincea J., Jones D. and Luthra R.: GSTT1 Genotype

Predicts for Failure to Achieve Molecular Remission in Adult Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. Presented at the Association for Molecular Pathology Annual Meeting, in Orlando, FL on November 16 – 19, 2006.

18. Habeebu S.S.M., Lopez-Terrada, D.: Development of a pyrosequencing-based quantitative

assay for JAK2 mutation in pediatric chronic myeloproliferative disorders. Presented at the Association for Molecular Pathology 2007 Annual Meeting, in Los Angeles, CA on November 6 – 10, 2007.

19. Habeebu S.S.M., Tuvin D., Lev D., Lazar A. and Lopez−Terrada D.: Beta-catenin codon 41

and 45 mutations are frequent in aggressive fibromatosis (desmoid tumor) and are useful markers in their differential diagnosis. Presented at the Association for Molecular Pathology 2007 Annual Meeting, in Los Angeles, CA on November 6 – 10, 2007.

INVITED SEMINARS 1. “In Situ Hybridization.” Duncan Guthrie Institute of Medical Genetics, Glasgow, U.K., July

1989. 2. “Non-isotopic Detection Systems for In Situ Hybridization.” Clinical Molecular Genetics

Society’s Workshop. Leeds General Infirmary, Leeds, U.K., September 1989. 3. “In Situ Hybridization: Detection Systems and Chromosome Painting.” Medical Research

Council Radiobiology Unit, Oxon, U.K., October 1989. 4. “Non-isotopic Detection Systems for In Situ Hybridization: Applications and Methods.”

Centre for Human Genetics, Sheffield, U.K., November 1989. 5. “Chromosome Painting.” Department of Cytopathology and Cytogenetics, St. Mary’s

Hospital, London, U.K., January 1990. 6. “In Situ Hybridization: Applications and Chromosome Painting.” West Midlands Regional

Genetic Services. Birmingham, U.K., February 1990. 7. “In Situ Hybridization: An Overview.” Guest Lecture, Clinical Molecular Genetics Society.

Birmingham, U.K., April 1991. 8. “Fluorescent In Situ Hybridization.” Pathological Society of Great Britain and Ireland.

London, U.K., January 1994.

9 of 12

9. “The Genetics of Human Sex Determination.” Children’s Mercy Hospital, Kansas City, MO, November 2004.

10. “Molecular Diagnostics in Oncology.” Texas Children’s Cancer Center, Houston, TX.

March, 2007. MEDICAL SCHOOL HONORS/AWARDS 1975/76 College/Faculty Prize, for the best aggregate performance in the basic medical

sciences 1975/76 Provost’s/Dean’s Prize, for the best performance in any subject in the basic

medical sciences 1975/76 Birmingham Prize, for the best aggregate performance in the basic medical

sciences 1975/76 K.B. Club Prize, for the best aggregate performance in the basic medical

sciences 1976/77 College/Faculty Prize, for the best aggregate performance in the basic medical

sciences 1976/77 Provost/Dean’s Prize, for the best performance in any subject in the basic

medical sciences 1978/79 I. L. Oluwole Memorial Prize, for the best performance in Preventive and Social

Medicine 1979/80 Nicholson Prize, for the best performance in Pathology 1979/80 Late George Ademola Memorial Prize, for the best aggregate performance in the

final year 1979/80 G. O. Falemi Memorial Prize, for the best aggregate performance in Medicine

and Preventive and Social Medicine OTHER AWARDS 1969–1973 Bendel State Scholarship (Nigeria), for high school education 1973–1974 Bendel State Automatic Scholarship (Nigeria), for pre-medical education 1973–1974 Scholarship of the Federal Government of Nigeria, for medical education 1977–1980 Scholarship of the College of Medicine, University of Lagos (Nigeria), for medical

education

10 of 12

1986–1989 The Commonwealth Scholarship (United Kingdom), for postgraduate education in Medical Genetics in the United Kingdom

1989 Student International Travel Award, by the International Human Gene Mapping

Organization, for the 10th International Human Gene Mapping Conference, held in New Haven, 1989

1994–1997 Kansas Health Foundation Grant, for postdoctoral research training 2007 The American Society for Investigative Pathology Travel Award, through the

auspices of the FASEB Minority Access to Research Careers Program, for the Association for Molecular Pathology 2007 Annual Meeting, in Los Angeles, CA on November 6 – 10, 2007.

SOCIETIES 1988–1990 Cambridge University Molecular Biology Society, United Kingdom.

1988–1990 Cambridge University Nigeria Society, United Kingdom.

1988–1992 Cambridge Philosophical Society, United Kingdom.

1989–1990 Cambridge Human Gene Mapping and Sequencing Society, United Kingdom.

1989–1993 Clinical Molecular Genetics Society of Great Britain.

1990–1994 The Blizard Club, The London Hospital Medical College, United Kingdom

1995–2001 Society of Toxicology, USA

2001– Kansas Society of Pathology

2002– College of American Pathologists

2003– United States and Canadian Academy of Pathology

2003– American Society for Clinical Pathology

2005– Association for Molecular Pathology

2005–2007 Texas Society of Pathology

2009– American Medical Association

VOLUNTEER EXPERIENCE 4/1994–9/1994 Research Scientist, Imperial Cancer Research Fund, London, U.K. I designed

and carried out experiments involving morphometric analysis, in situ hybridization and immunohistochemistry, applied to the pediatric tumor nephroblastoma.

11 of 12

12 of 12

LICENSURE Missouri State Full License, effective February 1, 2011. Kansas State Full License, effective December 4, 2009. Full licensure with the Nigerian Medical Council; effective April 1981. Certified by the ECFMG, January 2000. Certified in Anatomic and Clinical Pathology by the American Board of Pathology, July 2011. LANGUAGE FLUENCY English, the official language of Nigeria Agbede, a Nigerian language Yoruba, another Nigerian language HOBBIES/INTERESTS Computing, Photography, Mysteries, and Sightseeing.